Aptar Pharma’s innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been announced as the approved delivery device for Bausch+Lomb’s Levofree Multidose in France. This marks the first approval by the French National Agency for Medicines and Health Products Safety (ANSM) for Aptar Pharma’s Ophthalmic Dispenser.
Aptar Pharma has been working closely with Bausch+Lomb, one of the world’s leading Eye Care companies, to achieve this first ANSM approval of an Eye Care product in its multidose device. The approval has further expanded the regulatory acceptance of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for preservative-free Eye Care formulations.
With more than 150 commercial references worldwide, Aptar Pharma’s Ophthalmic Squeeze Dispenser meets key industry and patient needs for Eye Care by delivering improved patient safety, accurate design and product integrity. The ergonomic intuitiveness of the squeezable container with a low actuation force contributes to the high levels of acceptance. The Eye Care delivery solution is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions, while it is also the first and only FDA-reviewed delivery system for multidose, preservative-free Eye Care products.
“Our Ophthalmic Dispenser technology has been a great success for our customers,” explained Matthias Birkhoff, Vice President Business Development, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the French ANSM with confidence.”
For full details, download our press release here.
